第30回日本乳癌学会学術総会 第30回日本乳癌学会学術総会

Program

Special Lecture 1

Application of Supercomputer and AI to Precision Medicine

Chair : Yasuo Miyoshi Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo College of Medicine
Speaker : Yasushi Okuno Graduate School of Medicine, Kyoto University

Special Lecture 2

Deep Medicine: AI brings us heartful medical care!

Chair : Yasuo Miyoshi Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo College of Medicine
Speaker : Yusuke Nakamura National Institutes of Biomedical Innovation, Health and Nutrition 

Special Session 1

Current status of drug development 1: New drug development

Development of novel drug therapies will be discussed, showing the process of how a drug is selected from various candidates to be examined before conducting a first-in-human study.


Chair : Shinji Ohno Breast Oncology Center, Cancer Institute Hospital
Masakazu Toi Kyoto University
Research and Development of Antibody-Drug Conjugate (ADC) in Daiichi Sankyo
Speaker : Takashi Kagari Group I, Oncology Research Laboratories I, Research Function, R&D Division, Daiichi Sankyo Co., Ltd.
Organic Synthetic Technology based on Natural Product Chemistry - Leading to New Modality -
Speaker : Kenichi Nomoto Oncology Business Group, Eisai Co., Ltd.
Development of the medium-sized peptide activating of tumor suppressor to overcome therapy resistance in breast cancer
Speaker : Toyomasa Katagiri Div. Genome Med., Inst. Adv. Med. Sci., Tokushima Univ.
Therapeutic In Vivo Synthetic Chemistry
Speaker : Katsunori Tanaka Biofunctional Synthetic Chemistry Laboratory, RIKEN Cluster for Pioneering Research / Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Tokyo Institute of Technology

Special Session 2

Current status of drug development 2: Global extension of Clinical trial

Current and future directions for future development of novel drug therapies will be discussed, focusing on how a global clinical study overseas is proposed and developed, and how the Japanese market is viewed mainly in terms of worldwide development.


Chair Hiroji Iwata Department of Breast Oncology, Aichi Cancer Center
Shigehira Saji Department of Medical Oncology, Fukushima Medical University
Hitting earlier, harder and smarter: the future of cancer care
Speaker Susan Galbraith Head of Oncology Research and Development AstraZeneca, UK
Drug development and extension to a global clinical study: Japan participation
Speaker Vassiliki Karantza Merck & Co., Inc., Kenilworth, NJ, USA
Japan: A full seat at the table?
Speaker Alexander Gee Senior Director, Pricing and Access Parexel International, UK
Access to Oncology Drugs in Japan in the Era of Global Drug Development
Speaker Emi Noguchi Office of New Drug V, Pharmaceuticals and Medical Devices Agency

Presidential Lecture

Connecting to Future Generations of Breast Cancer Treatment and Clinical Study: My steps of 22 years

By looking back on my journey of 16 years in clinical and basic research and 22 years in breast cancer treatment, I will send a message to physicians contributing to future generations.


Chair : Sinzaburo Noguchi Director, Hyogo Prefectural Nishinomiya Hospital
Speaker : Yasuo Miyoshi Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo College of Medicine

Proposal to the future generations

Nurturing future generations leaders in Japan and overseas

In the session, our activities in Japan and overseas will be introduced to discuss future challenges in the training of future generations leaders.


Chair Shigeru Imoto Department of Breast Surgery, School of Medicine Kyorin University
Yasuo Miyoshi Division of Breast and Endocrine Surgery, Department of Surgery, Hyogo College of Medicine
Why we need a next-generation oncology leader? MD Anderson Cancer Center.
Speaker Ueno Naoto Department of Breast Medical Oncology The University of Texas MD Anderson Cancer Center
Speaker Takabe Kazuaki Roswell Park Comprehensive Cancer Center University at Buffalo Jacobs School of Medicine and Biomedical Sciences, the State University of New York Tokyo Medical University, Yokohama City University, Niigata University, Fukushima Medical University
Developing the Next Generation of Leaders in Japan - How to Expand Multidisciplinary Breast Cancer Care and Produce the Evidence from Japan
Speaker Akihiko Shimomura Dept. of Breast and Medical Oncology
Dept. of Genetic Medicine
Dept. of General Medical Oncology
National Center for Global Health and Medicine

Symposium

Recent advances in the personalized treatment for ER-positive/ HER2-negative breast cancer

We would discuss about the appropriate indications of chemotherapy, endocrine therapy and molecular targeted therapy, based on the biological background of each type of agents.

Novel stream of anti-HER2 therapy

We would review the clinical development of new anti-HER2 therapies and discuss about their positioning.

Therapeutic strategies for triple-negative breast cancer; DNA damage response and immunoreactivity

Therapeutic strategies against triple-negative breast cancer will be discussed by experts in individual fields, mainly covering PARP inhibitors against homologous recombination deficiency and the neoantigen- and cGAS-STING-activated tumor-immune systems triggered by DNA damage.

Axillary management for patients converting from cN+ to ycN0 through neoadjuvant chemotherapy.

There is a trend toward de-escalating axillary surgery in node-positive breast cancer patients who have achieved a good response of the axilla to neoadjuvant chemotherapy. A lack of consensus concerning axillary management in these patients has resulted in a large variety of axillary imaging diagnoses and treatment strategies worldwide. This session shares the axillary management practice including surgical videos for these patients in Europe, Canada, Korea, and Japan.

Survivorship Practice and Prospects for Future Generations

Survivorship care has become increasingly important for support of the recuperation and lives of breast cancer patients. This symposium will discuss the evidence and practice for exercise, women’s healthcare, psychosocial support, PRO, and advance care planning, including perspectives on medical cooperation and medical economics.

Development of artificial intelligence in breast imaging diagnosis

Mammography and ultrasonography are widely used for everything from breast cancer screening to diagnostic settings of breast cancer. In recent years, tomosynthesis and ABUS, which generate huge amounts of image data, have increased the burden on the diagnostic radiologist.
In order to reduce the burden on the physician, artificial intelligence (AI) continues to advance with technical improvements, and some AI-based medical devices have been approved. This session shares information on the current status of AI in breast imaging and the potential for introduction of the AI into medical practice in the future.

Challenges for AYA Breast Cancer Patients: Pregnancy, Childbirth and Future Prospects

Promotion services for fertility preservation were initiated in 2021. Fertility preservation in breast cancer patients who desire to bear children became one of the standards of care, leading to demand for more rapid establishment of a coordinated approach with cancer treatment and reproductive medicine. On the other hand, post-treatment pregnancy/delivery in breast cancer patients is an area requiring coordinated decision-making of the patient and healthcare professionals, frequently showing uncertain evidence. This session will discuss evidence on fertility preservation and post-treatment pregnancy/delivery as well as future challenges for breast cancer patients.

Beyond BRCA: Management of hereditary breast cancer associated with genes other than BRCA1/2

BRCA is now examined as a routine aspect of mammary care. This session will discuss other types of hereditary breast cancer related to factors such as Li-Fraumeni syndrome in patients with early-onset breast cancer tested negative for BRCA, hereditary breast cancer as a secondary finding identified by a cancer gene panel, and genetic services following BRCA gene testing for mammary care, including the introduction of a multigene panel for the germ line.

Present and future of genome medicine-we all have a role

Genome medicine provides treatments coordinated for individual conditions based on gene alterations in cancer patients. Although drug therapies based on gene alterations are mainly conducted as the current genome medicine, it is expected that genomic data of patients will be also used for variety of treatment methods such as radiotherapy and immunotherapy. Further, genome medicine in the broad sense includes risk-reducing surgery and surveillance for hereditary breast cancer. Regarding the role of genome medicine in breast care, the outcomes to date and future possibilities will be considered from a wide perspective to discuss future challenges.

New Trends in Radiation Therapy for Breast Cancer

The roles of radiotherapy for breast cancer are changing as progress is made with surgical and drug therapies. In addition, adverse events, particularly late adverse events, continue to decrease with advances in radiotherapy technology. Radiotherapy is effective in various cases of breast cancer treatment. Active treatments for improving prognosis in oligomestastasis have attracted attention in recent years. This symposium will introduce technical advances and new trends for radiotherapy, followed by a discussion focusing on the current status and issues with encouraging broad use of the treatment in Japan.

HRQOL/PRO as an endpoint in cancer clinical trial

HRQOL, which has frequently been included as a secondary endpoint in clinical studies, is also selected as a primary endpoint in some research. The challenges, usability, and future development of HRQOL used as an endpoint in clinical studies will be described.

Lights and shadows of immunotherapy

We would discuss about the clinical development of immune checkpoint inhibitors for breast cancer, in terms of appropriate risk benefit balance.

Current topics in basic research on the mechanism underlying therapeutic strategies for each subtype of breast cancer

Experts will discuss the latest basic findings on four subtypes of breast cancer, focusing on the treatment methods.

Changes in breast cancer practice brought by new technologies including multigene assays and liquid biopsies

Multigene assays such as OncotypeDX are valuable as prognostic marker and are used as an index for selecting a treatment option in breast cancer patients. Liquid biopsy technologies for evaluation of gene alterations related with cancer from blood samples have been also advancing year after year, including the recent development of gene panel tests by liquid biopsy. It is expected that these technical innovations will be used in various approaches applied in breast cancer treatment, including early detection and monitoring of the relapse of cancer as well as real-time evaluation of resistance to treatment. Changes in diagnosis and treatment of breast cancer provided by new technologies such as multigene assays and liquid biopsy will be discussed.

The Creating Innovations in Medical Technology for Breast Cancer

It has been expected that the prognosis of breast cancer will improve with the introduction of innovative medical technology in clinical practice. Current conditions of innovative medical technologies under development in all fields related to breast cancer treatment will be shown, including software and hardware.

Win-Win Work Style Reform in Breast Cancer Practice

Physicians’ work style reform will be legislated in 2024. For breast cancer treatment, we will discuss the use of win-win strategies on actions for patients who are being followed after surgery, medical cooperation between hospitals and mammary gland clinics, various ways of working (e.g., shifting tasks to certified breast care nurses), and work style reform using digital transformation.

Pathology Session

Future generations pathology: Digital pathology, AI, and Genetic abnormalities

Pathological diagnosis such as histological diagnosis, immunohistochemistry, and ISH method plays an important role in many evaluations and judgments of treatment policy decisions for breast cancer treatment. Recently, high-throughput genome analysis and gene analysis techniques are being applied one after another to breast cancer treatment, such as multigene assays, oncogene panel tests, and blood cfDNA. Furthermore, machine learning for pathological digital images and analysis of artificial intelligence using neural networks and statistical methods are also progressing in the field of histopathology. Under these circumstances, we would like to consider how the field of pathological diagnosis can confront these new fields, show their uniqueness and superiority, introduce them, and develop the field of pathology.

Video Session

Connecting to Future Generations of Breast Cancer Surgery

This session will show a video introducing oncoplastic surgery, procedures for axillary node dissection, and treatments of benign conditions.

Medical Staff Session

Support for sexuality issues in breast cancer patients

Since mammary carcinoma that develops in the breast, an organ related to reproduction, can change the patients’ body image and clothing after surgery, and anticancer treatment can affect patients’ sexual lives and cause hair loss, there may be significant impact on patients’ sexuality. Sexuality is a private issue that is often difficult for patients to discuss with others. Despite being aware of this, healthcare professionals frequently cannot be involved in the issues directly. We hope that this session will provide you with an opportunity to consider the sexuality issues faced by breast cancer patients and methods of support in actual clinical practice.

Consideration of "emotional" support systems in breast cancer treatment

For the selection and continuation of treatments with full understanding by patients receiving breast cancer treatment, support and psychiatric intervention for anxiety and depressive states are required so as to prevent patients from being isolated. Due to the ongoing pandemic, patients and their families often worry about infection with COVID-19 and therefore hesitate to visit medical institutions with various pains. We hope this session will provide an opportunity to consider the ideal methods of selecting a treatment while helping to ensure the continuation of treatment supporting breast cancer patients as well as the “emotional” state of the patients and their families during the pandemic.

Case Studies to Consider Multidisciplinary Approach and Empowerment of Professions

Protocol-based Pharmacotherapy Management (PBPM) refers to implementation of a drug treatment by pharmacists using their pharmacological knowledge and techniques in cooperation with physicians and other professionals according to protocol agreed in advance with the physicians, pharmacists, and other professionals.
Practice of PBPM is expected to improve the quality of drug treatment and ensure safety in reducing the workload on physicians by exercising the pharmacists’ professional skills, resulting in an outstanding contribution to the development of future team medicine. In this session, physicians and pharmacists who have actually conducted PBPM will speak about the benefits and how it is applied.

Pharmacy Seminar

Discussion of pharmacotherapy practiced in collaboration with physicians and pharmacists

Protocol-based Pharmacotherapy Management (PBPM) refers to implementation of a drug treatment by pharmacists using their pharmacological knowledge and techniques in cooperation with physicians and other professionals according to protocol agreed in advance with the physicians, pharmacists, and other professionals.
Practice of PBPM is expected to improve the quality of drug treatment and ensure safety in reducing the workload on physicians by exercising the pharmacists’ professional skills, resulting in an outstanding contribution to the development of future team medicine. In this session, physicians and pharmacists who have actually conducted PBPM will speak about the benefits and how it is applied.

Educational Seminar:Diagnosis

Up-to-date Breast Imaging: Focus on Revised Guidelines for Mammography and Breast Ultrasound

Educational Seminar:Treatment

The evolution of the axillary and regional lymph node management in Breast Cancer

GBCC (KBCS) / JBCS Joint Session

Emerging issues in the management of HR+/ HER2- early breast cancer

JBCS / JOPBS Joint Symposium

Renovation/ Evolution of Oncoplastic Breast Surgery in Japan for Treating Breast Cancer

JBCS / JABCS Joint Session

Revised edition of Japanese standards of medical facilities required for further assessment of a perceived abnormality detected at breast cancer screening

JBCS / JCA Joint Symposium

Pioneering New Clinical Medicine from Basic Research

Meet the Expert